10-Q: Tivic Health Reports Q2 2025 Results

Tivic Health Systems reports a decrease in revenue for Q2 2025 due to reduced advertising spend, shifting focus to biopharma programs.

Summary

• Tivic Health Systems, Inc. reports financial results for the quarter ended June 30, 2025.
• Revenue decreased by 39% to $86,000 compared to $140,000 in Q2 2024, and decreased by 67% to $156,000 for the six months ended June 30, 2025, compared to $474,000 for the same period in 2024.
• The decrease in revenue is attributed to a reduction in advertising spend as the company focuses on its biopharma programs.
• Cost of sales decreased by 71% to $32,000 in Q2 2025 and decreased by 82% to $52,000 for the six months ended June 30, 2025.
• Research and development expenses increased by $353,000 in Q2 2025 and increased by $432,000 for the six months ended June 30, 2025, due to the addition of the biopharma program.
• Sales and marketing expenses increased to $426,000 for Q2 2025, but decreased to $605,000 for the six months ended June 30, 2025.
• Net loss was $(1.93) million in Q2 2025 and $(3.43) million for the six months ended June 30, 2025.
• Cash and cash equivalents totaled $1.2 million as of June 30, 2025.
• The company has entered into an Equity Purchase Agreement with Mast Hill Fund, L.P. for up to $25 million.
• The company has an exclusive license agreement with Statera Biopharma, Inc. for Entolimod.

Sentiment

Score: 3

Explanation: The filing contains a mix of positive and negative information, with a stronger emphasis on negative aspects such as revenue decline, net losses, and going concern uncertainty. The positive aspects, such as the Statera agreement and cost of sales reduction, are overshadowed by the financial challenges.

Positives

• Cost of sales decreased by 71% in Q2 2025 and decreased by 82% for the six months ended June 30, 2025, due to supply chain restructuring and lower overhead costs.
• Gross margin increased by 41% during the three months ended June 30, 2025, and increased by 25% during the six months ended June 30, 2025, due to supply chain restructuring and a move to a lower-cost logistics provider.
• The company has an Equity Purchase Agreement with Mast Hill Fund, L.P. for up to $25 million.
• The company has an exclusive license agreement with Statera Biopharma, Inc. for Entolimod.
• The company completed an optimization study for its non-invasive VNS device, with results expected later this year.

Negatives

• Revenue decreased by 39% in Q2 2025 and decreased by 67% for the six months ended June 30, 2025, due to reduced advertising spend.
• Net loss was $(1.93) million in Q2 2025 and $(3.43) million for the six months ended June 30, 2025.
• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
• The company expects revenues to decrease as it plans to reduce spending on advertising and marketing for ClearUP.
• The company may need to raise additional capital to continue operating its business and fund its planned operations.

Risks

• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
• The company may need to raise additional capital to continue operating its business and fund its planned operations.
• The company expects revenues to decrease as it plans to reduce spending on advertising and marketing for ClearUP.
• The company is subject to risks associated with global supply chain constraints, tariffs, and economic uncertainty.
• The company's success depends on its ability to successfully manufacture, secure regulatory approval for, and commercialize product candidates in its pipeline.
• The company may be unable to execute a monetization strategy for ClearUP and may need to consider a strategic divestiture or other exit of the business.
• The company's entry into biologic therapeutics requires it to develop relationships with new suppliers, which may adversely impact its ability to accurately forecast lead times and manufacturing costs for its TLR5 Program.
• The company may be at risk of further inventory write-downs in 2025 if it is unable to sell its current inventory of ClearUP products.
• The company is subject to risks associated with the ongoing conflicts between Russia and Ukraine and Israel and Hamas, which could lead to market disruptions and supply chain interruptions.

Future Outlook

The company expects revenues to decrease as it plans to reduce spending on advertising and marketing required to support sales of ClearUP. The company will continue to consider alternative ways to monetize ClearUP and expects to complete a strategic transaction or otherwise exit the consumer business by the end of the year. The company's near-term focus is to advance the development of its biopharmaceutical candidates and to ultimately achieve revenue through the sale of Entolimod.

Management Comments

• The company is shifting its focus from growing the ClearUP business to advancing its biologic and bioelectronic pipeline towards commercial outcomes.
• The company is intentionally maintaining a small core team and relying heavily on third-party service providers to carry out its operations.

Industry Context

The company's focus on immunotherapeutics and bioelectronic medicine aligns with broader industry trends in developing innovative treatments for neurologic, cardiac, and autonomic-related diseases. The acquisition of Entolimod positions the company in the acute radiation syndrome (ARS) market, which has received increased attention due to potential threats and the need for effective countermeasures.

Comparison to Industry Standards

• The company's revenue decline contrasts with the growth experienced by some other companies in the bioelectronic medicine and immunotherapeutics sectors.
• Companies like ElectroCore, which focuses on non-invasive vagus nerve stimulation, have shown varying revenue performance, highlighting the challenges in commercializing bioelectronic devices.
• In the immunotherapeutics space, companies such as Emergent BioSolutions, which develops and manufactures products for public health threats, including radiation exposure, serve as a benchmark for potential growth and market positioning.
• Tivic's reliance on third-party service providers is a common practice among smaller biotech companies to manage costs, but it also introduces risks related to control and quality.

Management Changes

Stakeholder Impact

• Shareholders: Dilution from potential equity offerings, uncertainty due to going concern warning.
• Employees: Potential for restructuring or layoffs due to cost-cutting measures.
• Customers: Potential changes in product availability and support for ClearUP.
• Suppliers: Potential changes in relationships and payment terms.
• Creditors: Increased risk due to financial instability.

Next Steps

• Continue to advance the development of biopharmaceutical candidates.
• Seek regulatory approval for new products.
• Complete a strategic transaction or otherwise exit the consumer business by the end of the year.
• Release the results of the optimization study for the non-invasive VNS device later this year.
• File a Biologics License Application (BLA) with the FDA for Entolimod.

Key Dates

Recommendation

Given the declining revenue, net losses, and a going concern warning, a sell recommendation is appropriate. The company's shift to biopharma is promising, but the financial instability and need for additional capital raise significant risks for investors.

Keywords

Tivic Health, Entolimod, ClearUP, biopharma, TLR5, VNS, financial results, SEC filing, immunotherapeutics, Mast Hill, Statera Biopharma, going concern